NCT05102292进行中（未招募）1 期
An Open Label, Multicenter Phase Ib/II Clinical Study to Evaluate Efficacy , Safety and PK of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation
Shanghai Henlius Biotech1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2021年12月10日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
The purpose of this study was to assess efficacy, safety and PK in anaplastic thyroid cancer (ATC) given HLX208 (BRAF V600E inhibitor).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Good Organ Function;
- •Expected survival time ≥ 3 months;
- •Advanced BRAF V600 ATC that have been diagnosed histologically;
- •At least one measurable lesion as per RECIST v1.1;
- •ECOG score 0-1.
排除标准
- •Pregnant or lactating women;
- •Previous treatment with BRAF inhibitors or MEK inhibitors;
- •A history of other malignancies within two years, except for cured cervical carcinoma in situ, basal cell carcinoma of the skin;
- •Severe active infections requiring systemic anti-infective therapy.
研究组 & 干预措施
HLX208
Experimental
Participants receive HLX208 450mg bid po
干预措施: HLX208 (Drug)
结局指标
主要结局
ORR
时间窗: up to 2 years
Objective response rate(assessed by independent radiological review committee (IRRC) based on the RECIST Version 1.1)
次要结局
- PFS(from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years)
- OS(from the date of first dose until the date of death from any cause，assessed up to 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
未知
2 期
A phase II study for anaplastic thyroid canceranaplastic thyroid cancerJPRN-UMIN000000482agoya university hospital20
Unknown
2 期
Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)Anaplastic Thyroid CancerNCT04574817Taizhou Hanzhong biomedical co. LTD66
已完成
2 期
Nintedanib(BIBF1120) in Thyroid CancerMedullary Thyroid Cancer (MTC)Differentiated Thyroid Cancer (DTC)NCT01788982European Organisation for Research and Treatment of Cancer - EORTC100
已完成
1 期
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)Solid TumorAnaplastic Thyroid CancerNCT01240590National Cancer Institute (NCI)27
终止
2 期
Trial Evaluating Gleevec in Patients With Anaplastic Thyroid CarcinomaThyroid CancerNCT00115739University of Michigan Rogel Cancer Center11